Merck Gets European Panel Backing for Keytruda in Two Gynecologic Cancers
Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.
MarketWatch4d
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...
Benzinga.com4d
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...
Seeking Alpha on MSN4d
Merck’s Keytruda label expanded in the U.S. for mesothelioma
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label expansion for its ...
Post-Op Keytruda Boosts Bladder Cancer Outcomes
Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...
Benzinga.com24d
Merck Pulls Plug On Two Keytruda Late-Stage Studies On Underwhelming Data
Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in combination with stereotactic body radiotherapy (SBRT) for stage I or II non-small cell lung cancer ...
Nasdaq3d
Merck's Keytruda Obtains its First FDA Approval for Mesothelioma
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...
Seeking Alpha8d
Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer
Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda as part of a combination regimen with Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) Lenvima has reduced the risk of disease progression or death by 34% in a ...
Yahoo Finance5d
Keytruda keys in on survival: Promising results in high-risk early-stage TNBC from KEYNOTE-522
The increase in AEs occurring in the Keytruda group could have a notable impact on its commercial uptake in TNBC. While Keytruda's efficacy data is strong, the higher rate of immune-related AEs ...
Business Insider3d
Merck & Company Buy Rating Justified by Keytruda’s Performance and Gardasil’s Market Potential
Charlie CY Yang has given his Buy rating due to a combination of factors, including the strong performance and potential of Merck’s key products, particularly Keytruda and Gardasil. The growth ...
Nasdaq1mon
Health Canada Approves Keytruda-Padcev Combo For Certain Patients With Urothelial Cancer
(RTTNews) - Thursday, Merck & Co., Inc. (MRK) announced that Health Canada has approved its blockbuster cancer drug Keytruda for yet another indication. Keytruda in combination with antibody-drug ...
Morningstar4d
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
The company (MRK) said the approval is the first for Keytruda to treat MPM in the U.S. and is in combination with pemetrexed and platinum chemotherapy. MPM is a rare and aggressive malignancy ...